Vir Biotechnology to present hepatitis delta trial data at AASLD 2026

October 5, 2026 4:05 PM

Vir Biotechnology, Inc. (Nasdaq: VIR) announced it will present Phase 2 SOLSTICE trial data on the combination of elebsiran and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found